相关实验视频

Updated: May 5, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

穿皮冠状动脉干预中不同支架策略的安全性和有效性:一个网络元分析

Waqas Ullah¹, Harigopal Sandhyavenu², Syeda Ramsha Zaidi³

¹Department of Cardiology, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.

|February 19, 2025

概括

较新的药物排泄支架 (DES),包括无聚合物氧化和聚合物永久性埃弗罗利/佐托利,与较旧的西罗利支架相比,显著减少了主要的心血管不良事件. 这些先进的DES还降低了支架血栓形成和心肌梗塞的风险.

科学领域:

心血管医学心血管医学
生物材料科学生物材料科学
干预心脏病学干预心脏病学

背景情况:

包括聚合物永久性,聚合物吸收性和无聚合物在内的各种药物排泄支架 (DES) 设计的比较有效性仍在争论中.
不同的排泄药物进一步使得接受皮肤冠状动脉干预 (PCI) 患者选择DES的选择更加复杂.

研究的目的:

在PCI后的患者中比较不同DES策略的有效性.
评估与不同DES配置相关的长期结果.

主要方法:

数字数据库的系统搜索确定了所有相关的随机对照试验.
一个网络元分析比较了各种DES组合与永久聚合物西罗利斯排泄支架.
主要终点是主要的不良心血管事件 (MACE),包括心血管死亡率,心肌梗塞 (MI) 和目标血管再血管化.

主要成果:

分析了314个随机对照试验,其中包括345,749名患者.
与无聚合物氧化物,聚合物永久性埃弗罗利斯和佐托利斯支架相比,与聚合物永久性西罗利斯支架相比,无聚合物氧化物,聚合物永久性埃弗罗利斯和佐托利斯支架的5年MACE降低.
无聚合物化氧化物支架显示,支架血栓形成和心脏病发作的一年风险显著降低.

结论:

较新的DES,特别是无聚合物化氧化物和聚合物永久性everolimus/zotarolimus,可显著减少长期缺血事件.
这些发现支持使用先进的DES来改善PCI后患者的治疗结果.

关键词:

药物释放的支架可以释放药物.这是Everolimus.聚合物可吸收的聚合物没有聚合物的无聚合物.聚合物-永久性聚合物这是西洛利斯 ( sirolimus).氧化 - 化 - 氧化这就是Zotarolimus.

更多相关视频

Novel Percutaneous Approach for Deployment of 3D Printed Coronary Stenosis Implants in Swine Models of Ischemic Heart Disease

Novel Percutaneous Approach for Deployment of 3D Printed Coronary Stenosis Implants in Swine Models of Ischemic Heart Disease

Published on: February 18, 2020

Fully Endoscopic Mitral Valve Repair with Percutaneous Cannulation of Groin Vessels

Fully Endoscopic Mitral Valve Repair with Percutaneous Cannulation of Groin Vessels

Published on: May 26, 2023

相关概念视频

Coronary Artery Disease V: Interprofessional Care

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...

Acute Coronary Syndrome IV: Interprofessional Care

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...

Angina IV: Management

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...